Effects of PI3K inhibitor LY294002 on expression of S-phase kinase associated protein 2 in human lens epithelial cells
Ji Li
Abstract
Ji Li
Abstract
Background The proliferation of residual human lens epithelial cells (LECs) after cataract surgery leads to the formation and development of posterior capsular opacification (PCO).Although a variety of studies have increased our understanding of the pathogenesis of PCO,the cellular mechanism underlying the development of the PCO is still unclear.Objective This study attempted to characterize the effect of PI3K inhibitor,LY294002,on the proliferation of human lens epithelial cells (LECs) and the expression of S-phase kinase associated protein 2 (Skp2) in vitro.Methods Human LECs strains (SRA01/04) were cultured in RPMI1640 medium containing 10% fetal bovine serum.25 μmol/L LY294002 with DSMO was added into the medium after 24 hours.Only the same volume of DSMO was used as control group.The inhibiting rate of LY294002 on the proliferation of human LECs was detected in 12 and 24 hours after addition of LY294002 using MTT assay.Expressions of Skp2 protein and mRNA in cultured LECs were detected using Western blot and real-time PCR in 24 hours after treatment of 25 μmol/L LY294002 respectively.The effect of LY294002 (25 μmol/L) on LECs cellular cycle was analyzed by flow cytometry.Results The A490 values of LECs were quite different between DSMO group and 25 μmol/L LY294002 group in both 12 hours and 24 hours after addition of LY294002 (t=4.899,P0.01;t=4.879,P0.01 respectively).Proliferation of LECs was significantly declined in 25 μmol/L LY294002 group compared with only DSMO group in both 12 hours and 24 hours (P0.01).In 24 hours after treatment of 25 μmol/L LY294002,both Skp2/β-actin value and Skp2/GAPDH value were decreased in comparison with only DSMO group (t=26.931,P0.01;t=5.17,P0.01 respectively).The percentage of LECs in G1 phase was significantly increased in 25 μmol/L LY294002 group compared normal control group (56.73%±1.35% vs 66.15%±2.63%) (t=5.605,P0.01),and that in S phase was evidently decreased in 25 μmol/L LY294002 group compared normal control group (37.32%±5.54% vs 27.34%±6.58%) (t=4.080,P0.05) in 24 hours after treatment of 25 μmol/L LY294002.Conclusion LY294002 can inhibit the proliferation of human LECs in vitro and arrest LECs to enter into S phase from G1 phase.These effects of LY294002 on LECs may associated with down-regulation of Skp2 expression.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Background The proliferation of residual human lens epithelial cells (LECs) after cataract surgery leads to the formation and development of posterior capsular opacification (PCO).Although a variety of studies have increased our understanding of the pathogenesis of PCO,the cellular mechanism underlying the development of the PCO is still unclear.Objective This study attempted to characterize the effect of PI3K inhibitor,LY294002,on the proliferation of human lens epithelial cells (LECs) and the expression of S-phase kinase associated protein 2 (Skp2) in vitro.Methods Human LECs strains (SRA01/04) were cultured in RPMI1640 medium containing 10% fetal bovine serum.25 μmol/L LY294002 with DSMO was added into the medium after 24 hours.Only the same volume of DSMO was used as control group.The inhibiting rate of LY294002 on the proliferation of human LECs was detected in 12 and 24 hours after addition of LY294002 using MTT assay.Expressions of Skp2 protein and mRNA in cultured LECs were detected using Western blot and real-time PCR in 24 hours after treatment of 25 μmol/L LY294002 respectively.The effect of LY294002 (25 μmol/L) on LECs cellular cycle was analyzed by flow cytometry.Results The A490 values of LECs were quite different between DSMO group and 25 μmol/L LY294002 group in both 12 hours and 24 hours after addition of LY294002 (t=4.899,P0.01;t=4.879,P0.01 respectively).Proliferation of LECs was significantly declined in 25 μmol/L LY294002 group compared with only DSMO group in both 12 hours and 24 hours (P0.01).In 24 hours after treatment of 25 μmol/L LY294002,both Skp2/β-actin value and Skp2/GAPDH value were decreased in comparison with only DSMO group (t=26.931,P0.01;t=5.17,P0.01 respectively).The percentage of LECs in G1 phase was significantly increased in 25 μmol/L LY294002 group compared normal control group (56.73%±1.35% vs 66.15%±2.63%) (t=5.605,P0.01),and that in S phase was evidently decreased in 25 μmol/L LY294002 group compared normal control group (37.32%±5.54% vs 27.34%±6.58%) (t=4.080,P0.05) in 24 hours after treatment of 25 μmol/L LY294002.Conclusion LY294002 can inhibit the proliferation of human LECs in vitro and arrest LECs to enter into S phase from G1 phase.These effects of LY294002 on LECs may associated with down-regulation of Skp2 expression.
Key concepts: LY294002, Western blot, SKP2, PI3K/AKT/mTOR pathway, Andrology, Flow cytometry, Fetal bovine serum, Molecular biology